Table 3 Characteristics of the participants with plasma proteome data at discharge, who were included in the HIV mechanistic analysis
Characteristics at discharge | HIV− (n = 179) | HIV+ (n = 38) | Total (n = 217) | |||
|---|---|---|---|---|---|---|
Demographic | ||||||
Sex – Males N (%) | 102 (57%) | 20 (53%) | 122 (56%) | |||
Age, months – Median (IQR) | 13.9 (8.9–17.8) | 14.9 (7.3–19.3) | 13.9 (8.9–17.9) | |||
Site | ||||||
Banfora | 35 (20%) | 2 (5.3%) | 37 (17%) | |||
Blantyre | 15 (8.4%) | 5 (13%) | 20 (9.2%) | |||
Kampala | 63 (35%) | 9 (24%) | 72 (33%) | |||
Kilifi | 20 (11%) | 8 (21%) | 28 (13%) | |||
Migori | 28 (16%) | 12 (32%) | 40 (18%) | |||
Nairobi | 18 (10%) | 2 (5.3%) | 20 (9.2%) | |||
Anthropometry | ||||||
MUAC (cm) | Median (IQR) Mean (SD) | 10.80 (10.15–11.30) 10.60 (±0.932) | 10.20 (9.58–11.06) 10.20 (±1.10) | 10.65 (10.00–11.30) 10.5 (±0.975) | ||
WAZ score | Median (IQR) Mean (SD) | −3.96 (−4.67 to −3.18) −3.93 (±1.22) | −4.52 (−4.98 to −3.44) −4.27 (±1.25) | −4.01 (−4.79 to −3.19) −3.99 (±1.23) | ||
WHZ score | Median (IQR) Mean (SD) | −2.95 (−3.84 to −2.20) −3.93 (±1.22) | −3.17 (−4.24 to −2.52) -4.27 (±1.25) | −3.01 (−3.91 to −2.22) −3.02 (±1.30) | ||
HAZ score | Median (IQR) Mean (SD) | −3.35 (−4.39 to −2.39) −3.32 (±1.68) | −3.63 (−4.59 to −2.10) −3.33 (±1.84) | −3.39 (−4.46 to −2.34) −3.32 (±1.70) | ||
Oedema – Yes | 15 (8.4%) | 2 (5.3%) | 17 (7.8%) | |||
Clinical illness at admission – N (%) | ||||||
Diarrhoea | 79 (44%) | 22 (58%) | 101 (47%) | |||
Pneumonia | 84 (47%) | 15 (39%) | 99 (46%) | |||
Malaria Positive (RDT) | 28 (16%) | 4 (11%) | 32 (15%) | |||
Sepsis | 5 (2.8%) | 2 (5.3%) | 7 (3.2%) | |||
On Co-trimoxazole prophylaxis and Antiretroviral treatment at admission – N (%) | ||||||
Co-trimoxazole prophylaxis | 2 (1.1%) | 15 (39%) | 17 (7.8%) | |||
Antiretroviral treatment (ART) | – | 9 (24%) | – | |||
